Glucagonoma Syndrome and Bronchial Carcinoma
Authors: Werner Hunstein
Journal: Annals of Internal Medicine (1988)

Brief Reports1 December 1988Glucagonoma Syndrome and Bronchial CarcinomaWerner Hunstein, MD, Lorenz H. Trümper, MD, Reinhard Dummer, MD, Karl Schwechheimer, MDWerner Hunstein, MDSearch for more papers by this author, Lorenz H. Trümper, MDSearch for more papers by this author, Reinhard Dummer, MDSearch for more papers by this author, Karl Schwechheimer, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-11-920 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptGlucagonoma syndrome is a rare but well-defined clinical entity caused by the excessive production of glucagon in an alpha cell tumor of the pancreas. The principal features of this syndrome, apart from a considerably elevated glucagon serum level, include a typical skin rash (necrolytic migratory erythema), diabetes mellitus or impaired glucose tolerance, weight loss, and anemia. The first case was reported by Becker and associates in 1942 (1), but the association of ectopic glucagon production and necrolytic erythema was defined as Glucagonoma syndrome as late as 1974 by Mallinson and colleagues (2).More than 120 cases have been described, allowing...References1. BeckerKahnRothman SDS. Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syphilol 1942;45:1069-75. CrossrefGoogle Scholar2. MallinsonBloomWarinSalmonCox CSAPB. A glucagonoma syndrome. Lancet. 1974;2:1-5. CrossrefMedlineGoogle Scholar3. SherwinJoshiHendlerFeligConn RPRPH. Hyperglucagonemia in Laennec's cirrhosis: the role of portal-systemic shunting. N Engl J Med. 1974;290:239-42. CrossrefMedlineGoogle Scholar4. Boden G. Insulinoma and glucagonoma. Semin Oncol. 1987;14:253-62. MedlineGoogle Scholar5. PrinzBadrinathBanerjiSparaganaDorschLawrence RKMMTA. Operative and chemotherapeutic management of malignant glucagon-producing tumors. Surgery. 1981;90:713-9. MedlineGoogle Scholar6. BloomPolak SJ. Glucagonoma syndrome. Am J Med. 1987;82(Suppl 5B):25-36. CrossrefMedlineGoogle Scholar7. Ratcliffe J. ACTH and related peptides in lung cancer. In: Havemann K, Sorenson G, Gropp C, eds. Peptide Hormones in Lung Cancer. New York: Springer-Verlag; 1985:46-55. CrossrefGoogle Scholar8. RosenRadosevich SJ. Biology of lung cancer. In: Bitran JD, Golomb, HM, eds. Lung Cancer. Orlando, Grune & Stratton, Inc.; 1988:35-54. Google Scholar9. RappersbergerWolff-SchreinerKonradWolff KEKK. Das Glukagonom-Syndrom. Hautarzt. 1987;38:589-98. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From the University of Heidelberg, West Germany. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByEndocrine paraneoplastic syndromes in lung cancerDegenerative and metabolic diseasesSystemic Disease and the SkinEndocrine paraneoplastic syndromes in lung cancerSíndrome del glucagonomaIatrogenic necrolytic migratory erythema: A case report and review of nonglucagonoma-associated necrolytic migratory erythemaNECROLYTIC ACRAL ERYTHEMA: A CUTANEOUS MARKER OE VIRAL HEPATITIS CCutaneous metastases of lung cancer. 1 December 1988Volume 109, Issue 11Page: 920-921KeywordsAnemiaDiabetes mellitusErythemaGlucagonGlucose intolerancePancreasPathology and laboratory medicineRashesWeight loss Issue Published: 1 December 1988 PDF DownloadLoading ...